Zamplo App Aims to Transform Radiation Therapy with Real-Time Patient Data
December 17, 2024 (Toronto, Ontario) – With support from OBIO’s Early Adopter Health Network (EAHN™), Zamplo Inc. collaborated with Toronto’s University Health Network (UHN) in a quality study of the efficacy of the company’s point-of-care platform to help the treatment journey of patients undergoing Radiation Therapy (RT) at UHN’s Princess Margaret Cancer Centre.
Zamplo is a platform that enables patients to collect, manage, and analyze their own health data. Through a user-friendly app, it helps patients make informed decisions and connect with others while on their healthcare journey.
Typically, weekly assessments are conducted for patients undergoing outpatient Radiation Therapy (RT) to effectively manage radiation side effects and any psychosocial distress. If patients’ symptoms arise outside of scheduled oncologist review clinics, however, patients have the option to either visit the Radiation Nursing Clinic during regular business hours or may be referred to their local Emergency Department. As part of the project, Zamplo’s platform aimed to improve the patient experience during these routine weekly assessments and to help them better manage RT-related side effects and psychosocial distress outside of regular business hours.
The project included a quality evaluation study to examine the efficacy of the company’s decentralized point-of-care platform when monitoring cancer patients during RT and after they had returned home. The study leveraged weekly and ad-hoc patient-reported outcomes (PROs) for the timely detection of toxic side effects, allowing for early follow-up after RT. Study participants included breast and prostate cancer patients where half of these patients received early intervention during the 12-week monitoring period, minimizing the onset and/or severity of side effects the patients were experiencing.
Dr. Jennifer Croke, Radiation Oncologist at Princess Margaret Cancer Centre, said “Zamplo offers a user-friendly platform making it easy for patients to keep track of their wellbeing and communicate changes to their healthcare team. On the clinician’s end, it enables the customization of any surveys designed to meet the unique needs of cancer patients with diverse symptoms, including self-management, education and medication intake. “Throughout our project, we saw an exceptionally high patient survey completion rate, highlighting the app’s suitability to support wellbeing of patients with several common cancer types,” she added.
Dr. Maura Campbell, President and CEO of OBIO®, stated that “Through the EAHN™ program, OBIO® is delighted to support Zamplo, an Alberta-based company, to bring them to the Ontario market. The proven benefits of the Zamplo app to better utilize healthcare human resources and improve patient outcomes are a testament to the need for innovative solutions to expand the reach of the healthcare organization.”
OBIO’s EAHN™ program promoting the collaborative evaluations of home-grown technologies is bringing us a step forward towards personalized, data-driven healthcare with new technologies such as Zamplo’s.
Shaneel Pathak, CEO of Zamplo, said “We were excited to see our digital health platform improve patient communication and reduce hospital visits while receiving positive feedback from both patients and healthcare teams. This project has advanced the Quadruple Aim—enhancing patient experience, improving population health, reducing costs, and supporting healthcare providers. Through our collaboration with OBIO® and UHN’s Cancer Program, Zamplo is proud to play a key role in transforming care delivery and driving personalized, data-driven healthcare. I look forward to seeing continued impact across diverse patient populations.”
About Zamplo Inc.
Zamplo Inc. is a digital health company, founded in 2015. Zamplo has created a person-centred connected health platform that provides a central location for individuals to track their whole health data while staying connected to their clinicians, caregivers, researchers, and the health community.
With informed consent, the Zamplo app can collect PROs data between participants and researchers through an integration with the electronic data capture platform, Zamplo Research. This integration supports patient-centred research by streamlining study enrolment, providing tools for PRO collection, and focusing on participant engagement and quality of life. Researchers and clinicians can engage participants in their own care as participants retain control of their data and can access their personal health information to make more informed decisions. To learn more, visit: www.zamplo.org.
About OBIO®
OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development, and advocacy to address the needs of the next generation of companies developing innovative human health products. For more information, please visit obio.ca and follow OBIO® on LinkedIn and X.
Media contacts:
Shaneel Pathak
CEO and Co-Founder | Zamplo Inc.
shaneel@zamplo.org
Bibaswan Ghoshal
Senior Director, Technology Adoption | OBIO®
bibaswanghoshal@obio.ca